Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Rhea-AI Summary

Theriva Biologics (NYSE American: TOVX), a clinical-stage company focused on developing cancer therapeutics in areas of high unmet need, has announced its participation in the upcoming Q1 Investor Summit Virtual.

The company's presentation will feature CEO Steve Shallcross and General Director Dr. Manel Cascallo, scheduled for Tuesday, March 11, 2025, at 12:30 PM ET. The management team will also engage in one-on-one meetings during the event.

ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Steve Shallcross, Chief Executive Officer, and Manel Cascallo, PhD., General Director will present at the Q1 Investor Summit Virtual. Theriva’s management team will participate in 1x1 meetings.

Q1 Investor Summit Virtual
Format: Presentation
Presenter: Steve Shallcross, CEO and Manel Cascallo, PhD., General Director
Presentation Date and Time: Tuesday, March 11, 2025, 12:30 PM ET
Webcast: Click Here

About Theriva™ Biologics, Inc.

Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com.  

For further information, please contact: 
Investor Relations: 
Kevin Gardner
LifeSci Advisors, LLC 
kgardner@lifesciadvisors.com 

FAQ

When is Theriva Biologics (TOVX) presenting at the Q1 Investor Summit Virtual?

Theriva Biologics will present on Tuesday, March 11, 2025, at 12:30 PM ET.

Who will represent TOVX at the Q1 Investor Summit Virtual presentation?

CEO Steve Shallcross and General Director Dr. Manel Cascallo will represent Theriva Biologics.

What type of meetings will TOVX management participate in during the Q1 Investor Summit?

The management team will participate in one-on-one meetings during the event.

What is the main focus of Theriva Biologics' (TOVX) therapeutic development?

Theriva Biologics focuses on developing therapeutics for cancer and related diseases in areas of high unmet need.